muscle disorder drug

Servier Stumbles in Muscle Disease as Drug From $1.5B Deal Fails Pivotal Test

Servier’s sevasemten came from the acquisition of the muscular dystrophy assets of Edgewise Therapeutics. While the small molecule had met the goal of a Phase 2 test in Becker muscular dystrophy, Servier said new results in a pivotal cohort do not show statistically significant benefit.

By Frank Vinluan

BioPharma, Pharma

Here’s Why Novartis Is Paying $500M to Acquire a Preclinical RNA Startup

Novartis’s acquisition of DTx Pharma brings a lead program for a rare disease with no FDA-approved therapies. But the deal could also help the pharma giant bring new RNA therapies to new places in the body, a top Novartis executive explained.

By Frank Vinluan